❌

Reading view

Targeting cysteinyl leukotriene receptor 1 reprograms tumor-promoting myelopoiesis and overcomes immune checkpoint therapy resistance

Nature Cancer, Published online: 19 May 2026; doi:10.1038/s43018-026-01174-7

Tang et al. identify cysteinyl leukotriene receptor 1 (CysLTR1) as a critical regulator of tumor-induced myelopoiesis, suggesting CysLTR1 targeting to sensitize tumors to immune checkpoint blockade.
  •  

Disrupted molecular glue complex drives RAS inhibitor resistance

Cancers evade RAS-targeting molecular glues through distinct alterations that converge on disrupting synthetic complex formation, exposing strategies for improved drug design and rational combination therapy.
  •  

An Agentic System for Rare Disease Diagnosis with Traceable Reasoning

arXiv:2506.20430v3 Announce Type: replace-cross Abstract: Rare diseases affect over 300 million individuals worldwide, yet timely and accurate diagnosis remains an urgent challenge. Patients often endure a prolonged diagnostic odyssey exceeding five years, marked by repeated referrals, misdiagnoses, and unnecessary interventions, leading to delayed treatment and substantial emotional and economic burdens. Here we present DeepRare, a multi-agent system for rare disease differential diagnosis decision support powered by large language models, integrating over 40 specialized tools and up-to-date knowledge sources. DeepRare processes heterogeneous clinical inputs, including free-text descriptions, structured Human Phenotype Ontology terms, and genetic testing results, to generate ranked diagnostic hypotheses with transparent reasoning linked to verifiable medical evidence. Evaluated across nine datasets from literature, case reports and clinical centres across Asia, North America and Europe spanning 14 medical specialties, DeepRare demonstrates exceptional performance on 3,134 diseases. In human-phenotype-ontology-based tasks, it achieves an average Recall@1 of 57.18%, outperforming the next-best method by 23.79%; in multi-modal tests, it reaches 69.1% compared with Exomiser's 55.9% on 168 cases. Expert review achieved 95.4% agreement on its reasoning chains, confirming their validity and traceability. Our work not only advances rare disease diagnosis but also demonstrates how the latest powerful large-language-model-driven agentic systems can reshape current clinical workflows.
  •  
❌